Towards shortening the duration of antibiotic therapy for Lyme borreliosis: a systematic review and meta-analysis
Authors:
- Alice RaffetinARAlice Raffetin
- Anna J. HenningssonAHAnna J. Henningsson
- Katharina OrnsteinKOKatharina Ornstein
- Pauline AriasPAPauline Arias
- Volker FingerleVFVolker Fingerle
- Solene Patrat-DelonSPSolene Patrat-Delon
- Daniel BremellDBDaniel Bremell
- Per Eric LindgrenPLPer Eric Lindgren
- Benoît JaulhacBJBenoît Jaulhac
- Klaus-Peter HunfeldKHKlaus-Peter Hunfeld
- Céline CazorlaCCCéline Cazorla
- 17 April 2025
- journal article
- review article
- Published by Springer Nature in Infection
- Vol. 53 (3) , 809-830
Abstract
Objectives Systematic review and meta-analysis on shortening antibiotic therapy for Lyme borreliosis (LB) patients. Methods Data sources: Medline, Google, and Google Scholar (queried from January 2022-February 2024), following the PRISMA method and the Cochrane Handbook. Eligibility criteria: Randomized clinical trials, comparative studies; clear definitions of LB, duration of antibiotics and outcome; follow-up ≥ 6–12 months. Meta-analysis included studies that examined three outcomes: treatment failure; residual symptoms; adverse events. Intervention: Short vs. extended antibiotic therapy for erythema migrans (≤ 10 days vs. > 10 days) and disseminated LB (≤ 21 days vs. > 21 days). Assessment of risk of bias. Independently, using the Cochrane Tools. Methods of data synthesis. Estimation of treatment effects based on a fixed-effect model (Mantel–Haenszel or Peto method), with odds ratio (OR) and 95% confidence intervals (CI). Results Thirty-eight full-text articles were examined (850 patients): 29 were included in the qualitative analysis; six in the meta-analysis. Heterogeneity was low (I2 = 0%). At 12 months, short-term treatment did not differ from long-term treatment in terms of failures (OR1.50, 95%CI[0.43–5.22]) and residual symptoms (OR0.95, 95%CI[0.66–1.37]), albeit with small samples. Conclusion This meta-analysis was underpowered to prove non-inferiority of shorter treatment, but suggests its safety for EM. Studies focusing on antibiotics duration, with sufficient sample sizes and clear outcomes, are warranted. Graphical AbstractKeywords
This publication has 58 references indexed in Scilit:
- Identification of Unambiguous Borrelia Peptides in Human Urine Using Affinity Capture and Mass Spectrometry2024
- A comparison of two treatment regimens of ceftriaxone in late Lyme diseaseWiener klinische Wochenschrift, 2005
- Treatment of lyme arthritisArthritis & Rheumatism, 1994
- Azithromycin versus penicillin V for the treatment of early lyme borreliosisInfection, 1993
- Azithromycin versus doxycycline for treatment of erythema migrans: Clinical and microbiological findingsInfection, 1993
- Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children — A prospective studyInfection, 1991
- Ceftriaxone Therapy of Chronic Inflammatory ArthritisArchives of internal medicine (1960), 1990
- A randomized trial of ceftriaxone versus oral penicillin for the treatment of early european lyme borreliosisInfection, 1990
- Cefotaxime versus penicillin in the late stage of lyme disease — prospective, randomized therapeutic studyInfection, 1990
- Cefotaxime vs Penicillin G for Acute Neurologic Manifestations in Lyme BorreliosisArchives of Neurology, 1989